{{Drugbox
| IUPAC_name        = <small><nowiki>(2S)-2-[[(3S,6S,9S,12S)-12-[[(2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoyl]amino]-6-benzyl-9-(1H-indol-3-ylmethyl)-5,8,11,14-tetraoxo-1,4,7,10-tetrazacyclotetradecane-3-carbonyl]amino]-4-methylpentanoic acid</nowiki></small>
| image             = Nepadutant.svg
| width             = 250
| CAS_number        = 183747-35-5
| ATC_prefix        = None
| ATC_suffix        = 
| PubChem           = 3086682
| DrugBank          = 
| IUPHAR_ligand = 2123
| ChemSpiderID      = 2343247
| C=45 | H=60 | N=10 | O=14 
| molecular_weight  = 965.016 g/mol
| SMILES = CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CNC(=O)C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)Cc2ccccc2)Cc3c[nH]c4c3cccc4)NC(=O)[C@H](CC(=O)N[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)NC(=O)C)N
| StdInChI          = 1S/C45H60N10O14/c1-21(2)13-31(45(67)68)53-43(66)32-19-48-34(58)17-30(50-39(62)26(46)16-35(59)55-44-36(49-22(3)57)38(61)37(60)33(20-56)69-44)42(65)52-29(15-24-18-47-27-12-8-7-11-25(24)27)41(64)51-28(40(63)54-32)14-23-9-5-4-6-10-23/h4-12,18,21,26,28-33,36-38,44,47,56,60-61H,13-17,19-20,46H2,1-3H3,(H,48,58)(H,49,57)(H,50,62)(H,51,64)(H,52,65)(H,53,66)(H,54,63)(H,55,59)(H,67,68)/t26-,28-,29-,30-,31-,32-,33+,36+,37+,38+,44+/m0/s1
| StdInChIKey       = NPSVXOVMLVOMDD-SXRVEDALSA-N
| bioavailability   = <3% ([[Mouth|oral]])<ref name="AcademicPress1999">{{cite book|title=Annual Reports in Medicinal Chemistry|url=https://books.google.com/books?id=pJ1TIGO9VVYC&pg=PA56|date=8 September 1999|publisher=Academic Press|isbn=978-0-08-058378-5|pages=56–}}</ref>
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 44 minutes ([[intravenous|IV]])<ref name="AcademicPress1999" />
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = [[Injection (medicine)|Injection]]<ref name="AcademicPress1999" /><ref name="Holzer2004">{{cite book|author=Peter Holzer|title=Tachykinins|url=https://books.google.com/books?id=Fo4bKOwXbgsC&pg=PA224|date=17 June 2004|publisher=Springer|isbn=978-3-540-20690-3|pages=224–226}}</ref>
}}

'''Nepadutant''' ([[International Nonproprietary Name|INN]]) (code name '''MEN-11420''') is a [[glycosylation|glycosylated]] [[bicyclic]] [[cyclic peptide|cyclo]][[hexapeptide]] [[drug]] which acts as a highly [[binding selectivity|selective]] [[NK2 receptor|NK<sub>2</sub> receptor]] [[receptor antagonist|antagonist]].<ref name="Holzer2004" /><ref name="Regitz-Zagrosek2012">{{cite book|author=Vera Regitz-Zagrosek|title=Sex and Gender Differences in Pharmacology|url=https://books.google.com/books?id=-r02bdyoSEgC&pg=PA489|date=2 October 2012|publisher=Springer Science & Business Media|isbn=978-3-642-30726-3|pages=489–}}</ref><ref name="Britain)2003">{{cite book|author=Royal Society of Chemistry (Great Britain)|title=Amino Acids, Peptides and Proteins|url=https://books.google.com/books?id=WcMdAQAAMAAJ|date=January 2003|publisher=Royal Society of Chemistry|isbn=978-0-85404-242-5}}</ref> It was developed by the [[Menarini|Menarini Group]] and investigated for the treatment of [[functional gastrointestinal disorder]]s and [[asthma]] but was never marketed.<ref name="Regitz-Zagrosek2012" /><ref name="Frank2011">{{cite book|author=Barbara Frank|title=Women's Issues in Gastroenterology, An Issue of Gastroenterology Clinics|url=https://books.google.com/books?id=1naXWRfNZIMC&pg=PT54|date=29 June 2011|publisher=Elsevier Health Sciences|isbn=1-4557-1220-5|pages=54–55}}</ref><ref name="Jancso2008">{{cite book|author=Gabor Jancso|title=Neurogenic Inflammation in Health and Disease|url=https://books.google.com/books?id=yvsEGxG5gNcC&pg=PA297|date=27 November 2008|publisher=Elsevier|isbn=978-0-444-53229-9|pages=297–}}</ref>

==See also==
* [[GR-159,897]]
* [[Ibodutant]]
* [[Saredutant]]

==References==
{{Reflist|2}}


{{Drugs for functional gastrointestinal disorders}}
{{Drugs for obstructive airway diseases}}
{{Neurokinin receptor modulators}}

[[Category:Acetamides]]
[[Category:Amines]]
[[Category:Antispasmodics]]
[[Category:Bronchodilators]]
[[Category:Indoles]]
[[Category:NK2 receptor antagonists]]


{{nervous-system-drug-stub}}